Impact of a Histamine H2 Receptor Antagonist (H2RA) on the Pharmacokinetics (PK) of Telaglenastat in Healthy Subjects
Status:
Completed
Trial end date:
2020-12-08
Target enrollment:
Participant gender:
Summary
This study is designed to formally evaluate the impact of famotidine, an H2R antagonist, on
the pharmacokinetics of telaglenastat.
This study will be conducted in up to 22 healthy volunteers, who meet all of the inclusion
criteria and none of the exclusion criteria. The study is double-blinded, randomized 2-way
crossover in design.
Subjects will receive four 200 mg tablets of telaglenastat either in the presence or absence
of 20 mg famotidine (H2R-antagonist) with a 4-day wash-out period in between each regimen.